Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Heidrun Bosch Traberg"'
Autor:
Yutaka Seino, Hideaki Miyoshi, Heidrun Bosch Traberg, T V S Divyalasya, Keiji Nishijima, Yasuo Terauchi
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 8, Pp 1321-1329 (2022)
ABSTRACT Aims/Introduction The present trial compared the efficacy and safety of once‐daily liraglutide 1.8 mg with liraglutide 0.9 mg in Japanese patients with type 2 diabetes to assess the incremental effects of liraglutide 1.8 mg in those who ex
Externí odkaz:
https://doaj.org/article/1fc252900df9478ab8966830b33cfd82
Autor:
Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Søren Rasmussen, Linda G. Mellbin
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-11 (2023)
Abstract Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the association between majo
Externí odkaz:
https://doaj.org/article/c520c57dfa9343559d55cf333ed71c54
Autor:
Peter Rossing, Florian M M Baeres, George Bakris, Heidrun Bosch-Traberg, Mette Gislum, Stephen C L Gough, Thomas Idorn, Jack Lawson, Kenneth W Mahaffey, Johannes F E Mann, Henriette Mersebach, Vlado Perkovic, Katherine Tuttle, Richard Pratley
Publikováno v:
Nephrology Dialysis Transplantation.
BackgroundChronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D, and some reduce the risk of cardiovascu
Autor:
Katherine R. Tuttle, Heidrun Bosch-Traberg, David Z.I. Cherney, Samy Hadjadj, Jack Lawson, Ofri Mosenzon, Søren Rasmussen, Stephen C. Bain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c53dcc934e6f5ec71bc05c929d5e11
https://cronfa.swan.ac.uk/Record/cronfa63332
https://cronfa.swan.ac.uk/Record/cronfa63332
Autor:
Vlado Perkovic, Florian Baeres, George Bakris, Heidrun Bosch-Traberg, Thomas Idorn, Kenneth Mahaffey, Johannes Mann, Henriette Mersebach, Peter Rossing, Katherine Tuttle, Richard Pratley
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Chronic kidney disease (CKD) in type 2 diabetes (T2D) is the most common cause of kidney failure. Despite treatment advances, there is still a large unmet need to prevent CKD progression, which can increase the risk for cardiovasc
Autor:
Ling Li, David D. Dore, Najat Ziyadeh, Donnie Funch, Heather Norman, John D. Seeger, Helge Gydesen, Atheline Major-Pedersen, Heidrun Bosch-Traberg, Kathleen Mortimer
Publikováno v:
Diabetes, Obesity & Metabolism
Aims Both acute pancreatitis (AP) and pancreatic cancer (PC) have been areas of focus for studies of incretin drugs. This 5‐year prospective cohort study aimed to quantify possible associations between liraglutide and risk of AP and PC as compared
Autor:
Najat Ziyadeh, Douglas S. Ross, Li Zhou, Atheline Major-Pedersen, David D. Dore, John D. Seeger, Kathleen Mortimer, Donnie Funch, Helge Gydesen, Eva W. Ng, Heidrun Bosch-Traberg
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Donnie Funch,1 Kathleen Mortimer,1 Najat J Ziyadeh,1 John D Seeger,1 Li Zhou,1 Eva Ng,1 Douglas Ross,2,3 Atheline Major-Pedersen,4 Heidrun Bosch-Traberg,5 Helge Gydesen,6 David D Dore1,7 1Optum Epidemiology, Boston, MA, USA; 2Massachusetts General Ho
Autor:
Dorte Bjerre Steensgaard, Jesper Søndergaard Marino, Lotte T Spang, Arne Staby, Nicoline Videbæk, Christina Bartholdy, Heidrun Bosch-Traberg, Kim F. Haselmann, Désirée J Asgreen, Ole Schelde
Publikováno v:
Pharmaceutical Research. 37
Purpose Manufacturing processes for polypeptide/protein drugs are designed to ensure robust quality, efficacy and safety. Process differences introduced by follow-on manufacturers may result in changes in quality and clinical outcomes. This study inv
Autor:
Stuart J. Pocock, Michael A. Nauck, John B. Buse, Qing Ye, Alastair Gray, Heidrun Bosch-Traberg, H. Frimer-Larsen, Johannes F.E. Mann
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To assess health‐related quality of life (HRQoL) in people with type 2 diabetes (T2D) participating in the LEADER cardiovascular outcomes trial using the five‐dimension European Quality of Life questionnaire (EQ‐5D). Materials and methods
Publikováno v:
Journal of Diabetes Investigation
Aims/Introduction To determine the efficacy and safety of adding liraglutide to three different insulin regimens in Japanese patients with type 2 diabetes mellitus. Materials and Methods In this post‐hoc analysis, results from a 36‐week, randomiz